Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
Key Highlights
- ➤Insight Molecular Diagnostics (IMDX) prices 8,296,429 shares at $1.75 each
- ➤Offering includes pre-funded warrants for 275,000 shares at $1.7499 each
- ➤Gross proceeds expected at approximately $15 million before offering expenses
- ➤Company granted underwriter a 30-day option for 1,285,714 additional shares
- ➤Net proceeds will fund working capital, corporate purposes, and transplantation R&D
NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten public offering of 8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares of common stock at a price to the public of $1.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are being sold by iMDx. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 1,285,714 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about November 18, 2026, subject to customary closing conditions.
Get started
Create a free account to read the full story.
